A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
Running, not enrolling · Phase 3 · Has a placebo group
Conditions studied: Esophageal Squamous Cell Carcinoma
In brief
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
Key facts
- Study ID
- NCT04543617
- Run by
- Hoffmann-La Roche
- People needed
- 760
- Starts
- 2020-09-28
- Expected to finish
- 2027-03-31
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cancer Center of Kansas — Wichita, Kansas, United States
- Great Lakes Cancer Center — Williamsville, New York, United States
- Instituto de Investigaciones Metabolicas (Idim) — Buenos Aires, Argentina
- Fundacion Favaloro — Buenos Aires, Argentina
- Centro Oncologico Riojano Integral (CORI) — La Rioja, Argentina
- Princess Alexandra Hospital — Woolloongabba, Queensland, Australia
- Austin Health — Heidelberg, Victoria, Australia
- St John of God Hospital — Subiaco, Western Australia, Australia
- Tiroler Landeskrankenanstalten Ges.M.B.H. — Innsbruck, Austria
- Klinikum Klagenfurt am Wörthersee — Klagenfurt, Austria
- Ordensklinikum Linz Barmherzige Schwestern — Linz, Austria
- AKH - Medizinische Universität Wien — Vienna, Austria
- UZ Antwerpen — Edegem, Belgium
- UZ Leuven Gasthuisberg — Leuven, Belgium
- CHU de Liège (Sart Tilman) — Liège, Belgium
- Anyang Tumor Hosptial — Anyang, China
- Cancer Hospital Chinese Academy of Medical Sciences. — Beijing, China
- Affiliated Hospital of Bengbu Medical College — Bengbu, China
- Hunan Cancer Hospital — Changsha, China
- Heping Hospital Affiliated to Changzhi Medical College — Changzhi, China
- Changzhou Cancer hospital — Changzhou, China
- Sichuan Provincial Cancer Hospital — Chengdu, China
- West China Hospital, Sichuan University — Chengdu, China
- Chongqing Cancer Hospital — Chongqing, China
- Florida Cancer Specialists - Fort Myers (Broadway) — Fort Myers, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.